Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Editorial
Nature Reviews Drug Discovery 6, 97 (1 February 2007) | doi:10.1038/nrd2259
Same old story?
Abstract
The number of novel drugs that received approval by the US FDA in 2006 was close to an all-time low, with just 18 new molecular entities and 4 new biologic license applications being approved. However, looking beyond the gloomy data on drug approvals reveals some initial signs that the situation might finally begin to improve in coming years.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
